Further evidence supporting the use of letermovir for cytomegalovirus prophylaxis-It is not only leukopenia
- PMID: 40854486
- DOI: 10.1016/j.ajt.2025.08.030
Further evidence supporting the use of letermovir for cytomegalovirus prophylaxis-It is not only leukopenia
Conflict of interest statement
Declaration of competing interest The authors of this manuscript have conflicts of interest to disclose as described by American Journal of Transplantation. I. Helanterä has ongoing consultancy agreements with AstraZeneca, Hansa Biopharma, MSD, Sandoz, and Takeda; has received research funding from Hansa Biopharma, MSD, and Neovii; has received honoraria for lectures from Hansa Biopharma, Sandoz, and Takeda; and is an associate editor for American Journal of Transplantation. Both I. Helanterä and A. Åsberg were members of the Transplantation Society Fourth International CMV Consensus Guidelines group.
Publication types
LinkOut - more resources
Full Text Sources